Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Drugs in Development News & Deals for Alvesco HFA

    Client Email Product

    Alvesco HFA

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    12
    US DMFs Filed

    US DMFs Filed

    6
    CEP/COS Certifications

    CEP/COS Certifications

    4
    JDMFs Filed

    JDMFs Filed

    1
    Other Certificates

    Other Certificates

    3
    Other Suppliers

    Other Suppliers

    9
    API REF. PRICE (USD / KG)
    32,527

    API Market Place

    1
    INTERMEDIATES
    3
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    5
    Europe

    Europe

    11
    Canada

    Canada

    4
    Australia

    Australia

    2
    South Africa

    South Africa

    8
    Uploaded Dossiers

    Uploaded Dossiers

    5
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    144.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS
    96
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    4

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    7
    REF STANDARD

    EDQM

    1

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    left grey arrow
    right gray arrow
    • AEROSOL, METERED;NASAL - 0.037MG/INH
    • AEROSOL, METERED;INHALATION - 0.08MG/INH
    • AEROSOL, METERED;INHALATION - 0.16MG/INH
    • SPRAY, METERED;NASAL - 0.05MG/SPRAY
    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Japan Trials Asthma Drug Alvesco To Fight COVID-19

    Details:

    Institut Pasteur Korea has confirmed the effectiveness of AstraZeneca's ciclesonide in treating COVID-19 in a drug repositioning study by testing over 3,000 agents with infected cells.


    Lead Product(s): Ciclesonide

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 28, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    Coral Ciclesonide

    Access Virtual Booth

    Contact Supplier

    View Presentation

    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search